Competing interests
Nordisk, ABH, BBS, NJI, Dementia, LSS
BRAIN
Current/former employees of Cognition Therapeutics (Cognition): NJI, KML, RY, LW, MEH, SMC, AOC. Cognition paid consultants: CMY, JRC, RJG, CSD, MG, RM. LSS grants/fees: Eli Lilly, Merck, Roche/Genentech, Avraham, Boehringer Ingelheim, Neurim, Neuronix, Cognition, Eisai, Takeda, vTv, Abbott, Biogen, Novartis, Biohaven, outside this work. SD Chair of: Acumen Medical Scientific Advisory Board, Biogen Drug Monitoring Committee, Cognition Medical Advisory Board, DSMB for Prevail Pharmaceuticals and for pepinemab (Vaccinex, Inc.), Associate Editor of Neurotherapeutics, Editor for Dementia for UpToDate. HZ: SABs/as consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognition, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, Roche, is co-founder of Brain Biomarker Solutions (BBS, of GU Ventures Incubator; outside this work). KB: consultant, advisory boards, data monitoring committees Abcam, Axon, Biogen, Cognition, Julius Clinical, Lilly, MagQu, Novartis, Siemens Healthineers, Roche Diagnostics, is co-founder of BBS. International Patent WO 15/116923 pertains to this paper. YIS received a grant to the University of Pennsylvania supporting this research. ABH has lectured or served at SABs for Abbvie, Alector, BioArctic, Biogen, Eisai, Janssen, Novo Nordisk, Roche.